PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics reported positive topline results from a Phase 1 driving-simulation trial of GlyphAllo in healthy volunteers. The early-stage clinical result is a constructive development for the PureTech-founded entity, though the article provides no efficacy, safety, or financial details to quantify the program's broader commercial impact.